ClinicalTrials.gg
RecruitingNCT07190690DestinACSionUpdated Aug 10, 2026

Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions

An interventional study of ihtDEStiny® DES implanted and Xience™ DES implanted in Coronary Artery Disease, sponsored by Fundación EPIC. Recruiting at 20 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Fundación EPIC · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 33 studies in Coronary Artery Disease by Fundación EPIC — 13 open to participants now, 20 under way, none of them phase 3. Coronary Artery Disease · Fundación EPIC.

Planned enrollment
Largest of 13
2,100 · median 200
Started
2025
with 4 others
No phase
11 of 33
7 open now
Primary completion
2029-10
later than 18 of 19 live
Registered
30th of 33
by date

Among the 33 studies in Coronary Artery Disease by Fundación EPIC, this one has the largest planned enrollment of the 13 interventional ones that give a count, is one of 5 that started in 2025, is one of 11 with no phase, reaches primary completion later than 18 of the 19 other live ones, and was the 30th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

13 of the 33 studies in Coronary Artery Disease by Fundación EPIC are open now, in 7 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Coronary Artery Disease by Fundación EPIC, or all of them as a file.
02

Study summary

To evaluate the efficacy of the two DES (Drug Eluting Stent) used in terms of device-related adverse events at 12 months after PCI (Percutaneous Coronary Intervention).

To compare the clinical safety and efficacy by comparing net clinical events (defined as the combination of ischemic and hemorrhagic events) of the two DES used at 12 months after PCI.

Read the detailed description

To evaluate the efficacy of the two DES (Drug Eluting Stent) used in terms of device-related adverse events at 12 months after PCI (Percutaneous Coronary Intervention).

To compare the clinical safety and efficacy by comparing net clinical events (defined as the combination of ischemic and hemorrhagic events) of the two DES used at 12 months after PCI.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • Drug Eluting Stents
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients who meet ALL inclusion criteria will be included:

  • Patients aged ≥18 years, and
  • Patients diagnosed with an acute coronary syndrome (ACS), either SCASEST (Acute Coronary Syndrome without Persistent ST-Segment Elevation) or IAMCEST (Acute Myocardial Infarction with Persistent ST-Segment Elevation), for which they will undergo PCI, and
  • Patients with de novo lesions in vessels with a reference diameter of ≥2.25 mm and ≤4.5 mm in whom implantation of one or more DES is clinically indicated, and
  • Patients who have been informed of the characteristics of the study and have provided written .

Exclusion criteria

Exclusion Criteria:

Patients must not meet any of the following exclusion criteria:

  • Patients in cardiogenic shock according to the severity criteria defined by the Society of Cardiovascular Angiography and Interventions (SCAI): "C" (Classic Shock), "D" (Deteriorating) and "E" (Extremis).
  • Patients unable to provide .
  • Patients with a known or allergy to aspirin or any P2Y12 receptor inhibitor (clopidogrel, prasugrel, ticagrelor), heparin, contrast agents, or any of the components of DES.
  • Patients with active bleeding at the time of PCI requiring medical attention.
  • Patients with planned surgery within the next 3 months.
  • Patients with any medical condition that limits a of less than 12 months.
  • Patients participating in another clinical trial in which the primary endpoint was not met.
  • Pregnant or breastfeeding women of with a positive pregnancy test.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,100 participants (estimated)

Study arms

  • Other
    Active Comparator: ihtDEStiny® DES

    Device: ihtDEStiny® DES implanted

  • Other
    Experimental: Xience™ DES

    Device: Xience™ DES implanted

Interventions

  • DeviceihtDEStiny® DES implanted

    ihtDEStiny® DES implanted

  • DeviceXience™ DES implanted

    Xience™ DES implanted

06

What researchers measure

Primary outcomes

  1. EFFICACY: Device-oriented Composite Endpoint (DoCE)

    Composite clinical endpoint cardiac Rate at 12 months cause death, target vessel myocardial infraction (TV-MI), and Clinically individual target lesion revascularization (CI-TLR)

    Time frame: 12 months

  2. NACE

    Composite clinical endpoint Rate of all-cause death, any stroke, any MI, any revascularization and BARC type 3 or 5 bleeding events

    Time frame: 12 months

Secondary outcomes

  1. All-Cause Death Rate at 12 months

    All-Cause Death Rate at 12 months

    Time frame: 12 months

  2. All-Cause Death Rate at 24 months

    All-Cause Death Rate at 24 months

    Time frame: 12 months

  3. Cardiac Death Rate at 12 months

    Cardiac Death Rate at 12 months

    Time frame: 12 months

  4. Cardiac Death Rate at 24 months

    Cardiac Death Rate at 24 months

    Time frame: 12 months

  5. Myocardial Infarction Rate at 12 months

    Myocardial Infarction Rate at 12 months

    Time frame: 12 months

  6. Myocardial Infarction Rate at 24 months

    Myocardial Infarction Rate at 24 months

    Time frame: 12 months

  7. Periprocedural myocardial infarction Rate

    Periprocedural myocardial infarction Rate

    Time frame: PCI procedure

  8. Definite/Probable stent thrombosis rate at 12 months

    Definite/Probable stent thrombosis rate at 12 months

    Time frame: 12 months

  9. Definite/Probable stent thrombosis rate at 24 months

    Definite/Probable stent thrombosis rate at 24 months

    Time frame: 24 months

  10. Any stroke at 12 months

    Stroke Rate at 12 months

    Time frame: 12 months

  11. Any stroke at 24 months

    Stroke Rate at 24 months

    Time frame: 12 months

  12. BARC type 2 ,3 or 5 bleeding events at 12 months

    Bleeding events type 2, 3 or 5 defined by BARC (Bleeding Academic Research Consortium) criteria at 12 months

    Time frame: 12 months

  13. BARC type 2 ,3 or 5 bleeding events at 24 months

    Bleeding events type 2, 3 or 5 defined by BARC (Bleeding Academic Research Consortium) criteria at 24 months

    Time frame: 24 months

  14. Target vessel revascularization Rate at 12 months

    Target vessel revascularization Rate at 12 months

    Time frame: 12 months

  15. Target vessel revascularization Rate at 24 months

    Target vessel revascularization Rate at 24 months

    Time frame: 24 months

  16. Target vessel Failure (TVF) Rate at 12 months

    Target vessel Failure (TVF) Rate at 12 months

    Time frame: 12 months

  17. Target vessel Failure (TVF) Rate at 24 months

    Target vessel Failure (TVF) Rate at 24 months

    Time frame: 24 months

  18. Target Lesion Failure (TLF) Rate at 12 months

    Target Lesion Failure (TLF) Rate at 12 months

    Time frame: 12 months

  19. Target Lesion Failure (TLF) Rate at 24 months

    Target Lesion Failure (TLF) Rate at 24 months

    Time frame: 24 months

  20. Target Vessel Revascularization Rate (TVR) at 12 months

    Target Vessel Revascularization Rate (TVR) at 12 months

    Time frame: 12 months

  21. Target Vessel Revascularization Rate (TVR) at 24 months

    Target Vessel Revascularization Rate (TVR) at 24 months

    Time frame: 24 months

  22. Target lesion ischemia-guided revascularization Rate at 12 months

    Target lesion ischemia-guided revascularization Rate at 12 months

    Time frame: 12 months

  23. Target lesion ischemia-guided revascularization Rate at 24 months

    Target lesion ischemia-guided revascularization Rate at 24 months

    Time frame: 24 months

  24. Repeated revascularization Rate at 12 months

    Repeated revascularization Rate at 12 months

    Time frame: 12 months

  25. Repeated revascularization Rate at 24 months

    Repeated revascularization Rate at 24 months

    Time frame: 24 months

  26. Major Adverse Cardiac Events (MACE) Rate at 12 months

    Major Adverse Cardiac Events (MACE) Rate is defined as cardiac death, MI not clearly attributable to a non-intervention vessel, and clinically-indicated target lesion revascularization at 12 months

    Time frame: 12 months

  27. Major Adverse Cardiac Events (MACE) Rate at 24 months

    Major Adverse Cardiac Events (MACE) Rate is defined as cardiac death, MI not clearly attributable to a non-intervention vessel, and clinically-indicated target lesion revascularization at 24 months

    Time frame: 24 months

07

Study locations

20 of 20 sites recruiting
08

References and documents

Publications

  • de la Torre Hernandez JM, Otaegui I, Subinas A, Gomez-Menchero A, Moreno R, Rondan J, Munoz-Garcia E, Sainz-Laso F, Garcia Del Blanco B, Rumoroso JR, Diaz JF, Berenguer A, Gomez-Lara J, Zueco J. First-in-Man Evaluation of a Sirolimus-Eluting Stent With Abluminal Fluoropolymeric/Triflusal Coating With Ultrathin Struts by OCT at 9 Months' Follow-Up: The PROMETHEUS Study. Cardiovasc Revasc Med. 2021 Nov;32:18-24. doi: 10.1016/j.carrev.2020.12.025. Epub 2020 Dec 29. PubMed 33386256 ↗
  • Ploumen EH, von Birgelen C. Novel DES Aims at Full Thromboresistance: Another Promising Player on the Field? Cardiovasc Revasc Med. 2021 Nov;32:25-26. doi: 10.1016/j.carrev.2021.07.029. Epub 2021 Aug 11. No abstract available. PubMed 34391680 ↗
  • Linares Vicente JA, Sainz Laso F, Casanova Sandoval JM, Rumoroso Cueva JR, Gomez Menchero A, Gomez Hospital JA, Perez Guerrero A, Santos Martinez S, Fernandez Portales J, Romani S, Garcia Del Blanco B, Ocaranza Sanchez R, Urbano Carrillo C, Garcia San Roman K, Vinhas H, Cid Alvarez B, Sanchis Fores J, Telleria Arrieta M, Torres Bosco A, Pinar Bermudez E, Mendez Castro JJ, Lozano Ruiz de Poveda F, Perez de Prado A, De la Torre Hernandez JM. Long-term outcomes of hydrodynamic ultra-thin strut sirolimus-eluting stent with fluoropolymer containing triflusal: VELAZQUEZ-EPIC26 study. Cardiovasc Revasc Med. 2026 Mar;84:26-33. doi: 10.1016/j.carrev.2025.07.009. Epub 2025 Jul 17. PubMed 40713212 ↗
  • Zaman A, de Winter RJ, Kogame N, Chang CC, Modolo R, Spitzer E, Tonino P, Hofma S, Zurakowski A, Smits PC, Prokopczuk J, Moreno R, Choudhury A, Petrov I, Cequier A, Kukreja N, Hoye A, Iniguez A, Ungi I, Serra A, Gil RJ, Walsh S, Tonev G, Mathur A, Merkely B, Colombo A, Ijsselmuiden S, Soliman O, Kaul U, Onuma Y, Serruys PW; TALENT trial investigators. Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial. Lancet. 2019 Mar 9;393(10175):987-997. doi: 10.1016/S0140-6736(18)32467-X. Epub 2019 Feb 28. PubMed 30827782 ↗
  • Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, Onuma Y, Morel MA, van Es GA, Zuckerman B, Fearon WF, Taggart D, Kappetein AP, Krucoff MW, Vranckx P, Windecker S, Cutlip D, Serruys PW; Academic Research Consortium. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Circulation. 2018 Jun 12;137(24):2635-2650. doi: 10.1161/CIRCULATIONAHA.117.029289. PubMed 29891620 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Oct 2029, 45 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 45 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2025
First posted
Sep 24, 2025
StartActual
Dec 19, 2025
Primary completionEst.
Oct 15, 2029
CompletionEst.
Oct 15, 2030
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07190690
Lead sponsor
Fundación EPIC
Responsible party
Sponsor
First posted
Sep 24, 2025
Start date
Dec 19, 2025
Primary completion
Oct 15, 2029 (estimated)
Completion
Oct 15, 2030 (estimated)
Last update
Aug 10, 2026

Study contacts

Armando Pérez de Prado, MD, PhD
Contact
admin@fundacionepic.org
0034987876135
FUNDACION EPIC
Contact
iepic@fundacionepic.org
0034987876135

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion